Rockpointe

Rockpointe


Achieving Precision Care in Gastrointestinal Cancers

Treatment selection is largely dependent on the goals of therapy; however, sequencing of standard therapies with newly approved therapies as patients’ progress is a key factor in improving quality of care. The recent approval of new agents and advances in biomarker detection have supported the individualization of treatment and subsequent improvements in survival for patients with gastrointest...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Patients with radioactive iodine-refractory thyroid cancer (RAIR-DTC) have poor prognoses and, until recently, there were no effective targeted systemic therapies available for RAIR-DTC. Targeted therapies sorafenib and lenvatinib have been approved by the FDA for treating RAIR-DTC in the last 5 years. Along with these approved therapies, other targeted therapies, such as cabozantinib and vandet...
The Endocrine Society, Rockpointe Oncology

Collaborating with Patients to Improve IPF Care: Strategies to Enhance Patient QOL and Survival

Recent efforts to improve provider-patient communication and facilitate shared decision-making regarding treatments have been successful, as two-thirds of idiopathic pulmonary fibrosis (IPF) patients report being involved in discussions regarding their care. However, opportunities still exist to ensure alignment of patient and physician priorities and to provide clinicians with the most up-to-da...
The Potomac Center for Medical Education

Current Evidence-based Management of Idiopathic Pulmonary Fibrosis: Collaborating To Improve Patient Care

Despite the availability of guidelines for idiopathic pulmonary fibrosis (IPF) management and new effective treatments, wide variabilities in care still exist. These variations are due, in part, to the difficulties of making a differential diagnosis of IPF and the challenges of developing and implementing cross-functional multidisciplinary team initiatives. In order to improve health outcomes...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and American Lung Association

Evidence-based Updates in Non-Hodgkin’s Lymphoma

Significant advances in treatment with novel agents for B-cell non-Hodgkin’s lymphoma (NHL) have improved patient outcomes and survival. However, many patients are at high-risk of relapse, meriting a precision approach to reduce the rate of recurrence and improve outcomes. The identification of molecular subtypes, the persistence of clinical challenges, and the anticipated emergence of clinica...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Histopathological Patterns of Interstitial Lung Disease: A Multidisciplinary Approach to Distinguishing the Most Common Forms of Lung Fibrosis

Patients with interstitial lung disease (ILD) continue to suffer unacceptable delays in diagnosis and treatment initiation. Making an early and accurate diagnosis of ILD and its cause is key to initiating appropriate treatment and improving patient outcomes. This activity will use a case-based approach to address knowledge and practice gaps in ILD presentations and diagnoses, as well as to show ...
Potomac Center for Medical Education and Rockpointe

HRCT and the Radiologist’s Role in Diagnosing IPF

Use of a multidisciplinary team approach to the diagnosis and care of patients with idiopathic pulmonary fibrosis (IPF) has been shown to improve treatment and outcomes. However, patients with IPF continue to suffer unacceptable delays in diagnosis and initiation of optimal treatments. High-resolution computed tomography (HRCT) is recommended for all patients suspected to have idiopathic interst...
The Potomac Center for Medical Education

Integrating Immunotherapy for NSCLC

The emergence of checkpoint inhibitors (CTLA4, PD1, PD-L1) has reawakened an interest in immunotherapy to treat various malignancies. New agents have rapidly been approved for use in melanoma, bladder cancer, renal cell, lung cancer, and other malignancies. These agents have a unique toxicity profile requiring careful clinical assessment, rapid intervention, and aggressive management of side eff...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, Rockpoointe Oncology

Integrating New Therapies into Treatment Regimens for Gastric and Gastroesophageal Cancer

The recent inclusion of targeted biologic agents in guideline recommendations has provided oncologists with more treatment options and patients with the potential for improved outcomes. However, these additional options also increase the complexity of treatment selections and appropriate sequencing of treatments for patients with gastric and gastroesophageal (GEJ) cancers. Integrating New Thera...
The Potomac Center for Medical Education

Managing Psoriatic Arthritis to Improve Patient Outcomes

Many psoriatic arthritis (PsA) patients are not receiving medical treatment for their condition, even though they experience a poor quality of life due to the symptoms of PsA. Reasons for this undertreatment include physicians underestimating the systemic nature and psychosocial impact of PsA, a lack of physician knowledge of the current treatment goals and recommendations, and a lack of patient...
Potomac Center for Medical Education and Rockpointe

Metastatic Breast Cancer

While mortality rates for breast cancer are decreasing, metastatic breast cancer (MBC) remains incurable. This session will review new treatment options based on molecular and genetic information, the level of evidence used to formulate practice guidelines, as well as updates from ASCO 2017. New agents, including PARP inhibitors for those with appropriate mutations, will also be discussed. Clini...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Multiple Sclerosis Care in the Hospital Setting: Novel Neuroimaging Techniques, Individualized Treatment Strategies, and Management of Comorbidities

Early diagnosis in MS is imperative to minimize progression and improve patient quality of life. However, many patients with MS continue to receive delated diagnoses. In addition, a lack of coordination within the multidisciplinary management team can lead to inadequate management of MS-associated comorbidities. In order to help ensure accurate and timely diagnoses and improve care-team coordin...
The Potomac Center for Medical Education

Navigating New Options to Improve Outcomes in Multiple Myeloma

As new combinations and classes of agents emerge for the treatment of multiple myeloma (MM), community-based treatment teams require clarity on the optimal integration of recently approved and emerging agents into the relapsed/refractory landscape for MM. While high-dose chemotherapy is not appropriate for all patients, multiple options have emerged that demonstrate a clinical benefit and requir...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

New Treatments and Targets for Axial Spondyloarthritis: A Personalized Approach to Improve Outcomes

Ankylosing spondylitis (AS) is an immune-mediated chronic inflammatory disease that typically affects the sacroiliac (SI) joints. Patients with AS suffer from debilitating pain and joint fusion that severely limits their mobility and functional capacity. AS is a form of axial spondyloarthritis (axSpA), in which SI structural damage is visible on X-rays; the other form is non-radiographic axSpA, ...
Potomac Center for Medical Education and Rockpointe

Payment Models and Practice Changes: Meeting Requirements of OCM & MACRA

Recent legislation and policy has fast-tracked the shift of healthcare payment from volume- to value-based reimbursement under the Medicare Access and CHIP Reauthorization Act (MACRA) for oncology care. Today, oncologists have the option to be reimbursed for Medicare patients under the CMS Oncology Care Model (OCM), an alternative payment model spanning a 6-month chemotherapy episode-of-care. Th...
Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology

Precision Medicine and Impact of Therapeutic Drug Levels

Much has been written recently about the need for genetic testing and biomarkers to identify specific targets within cancers, recognizing that there are many subclones and individual differences within the malignancies that arise in patients, even in those with morphologically similar cancers. Another important aspect of cancer treatment is the need to optimize the dose and schedule of administe...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Redefining Care for BRCA and Other Familial-associated Cancers

Advances in molecular genetics and testing have refined the diagnosis, treatment, and follow-up for patients with BRCA and other familial genetic syndromes. As women with germline BRCA1 and BRCA2 mutations are at an increased risk for developing high-grade serous ovarian cancer, there are implications for genetic testing, family counseling, radiologic screening, and pharmaceutical choices in the...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Targeted Therapy for Skin Malignancies: Basal Cell Carcinoma, Melanoma, and Merkel Cell

Patients may not always be offered the most appropriate single and combination targeted therapies that have been proven effective in clinical trials. Currently available clinical data have practice-changing implications for medical oncologists, dermatologists, and related specialists treating skin malignancies. To stay up to date with the latest data, evidence will be presented related to the ro...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Targeting EGFR, T790M, ALK, and ROS1 in NSCLC

Oncology treatment teams are tasked with navigating through a steady increase in the number and complexity of molecular biomarkers that guide treatment decisions. FDA-approved companion tests have expanded testing options and provide uniformity of reporting, yet challenges in the clinical setting and the potential to negatively impact patient outcomes persist. As part of the continuum of care in...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Treatment Strategies in Chronic Leukemias and Introduction to CAR-T Therapy

Chronic lymphocytic (CLL) and chronic myelogenous (CML) leukemia are commonly diagnosed and treated by community oncologists. Whereas, in the past, these hematologic malignancies were considered incurable, new therapies have challenged that notion. Tyrosine kinase inhibitors (TKIs) annihilated the concept of CML as a poorly controlled disease, and most patients are now expected to live a normal...
Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology

Use of Oncology Quality Measures Where Do We Go from Here?

The new CMMI guidelines for physician reimbursement for patient care require some demonstration of quality and value in care delivery. Certain quality programs are available to oncologists (such as PQRS, QOPI, etc.). These assessments of quality require demonstration that specific guidelines are measured and followed within acceptable compliance targets. This session will address how these meas...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.